Astellas, a pharmaceutical company, received FDA approval for Xospata in November 2018. This drug is for treatment of adult patients who have relapsed or refractory acute myeloid leukemia with the FLT3 mutation.
On Monday at American Association for Cancer Research annual meeting, Astellas released Phase 3 data that showed that patients lived a median 9.3 months after therapy, compared with 5.6 months for those receiving salvage chemotherapy.
At the one-year mark, 37% of patients in the experimental arm of the study were still alive, while just 17% of chemo patients reached that mark.
Click here to read the entire article.